Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis.

[1]  S. Kornbluth,et al.  Mitotic phosphatase activity is required for MCC maintenance during the spindle checkpoint , 2016, Cell cycle.

[2]  Stephen L. Abrams,et al.  Targeting breast cancer initiating cells: advances in breast cancer research and therapy. , 2014, Advances in biological regulation.

[3]  A. Martelli,et al.  Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. , 2014, Advances in biological regulation.

[4]  K. Dorritie,et al.  STAT transcription factors in normal and cancer stem cells. , 2014, Advances in biological regulation.

[5]  J. McCubrey,et al.  Foreword: "Targeting signaling pathways in stem cells". , 2014, Advances in biological regulation.

[6]  F. E. Bertrand,et al.  NOTCH and PTEN in prostate cancer. , 2014, Advances in biological regulation.

[7]  J. Barata,et al.  PTEN and leukemia stem cells. , 2014, Advances in biological regulation.

[8]  J. McCubrey,et al.  Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment. , 2014, Advances in biological regulation.

[9]  B. Kolundžija,et al.  877: Changes of the white blood cells subsets in HER2 positive breast cancer patients treated with trastuzumab , 2014 .

[10]  Stephen L. Abrams,et al.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention , 2014, Oncotarget.

[11]  O. Maertens,et al.  An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer. , 2014, Advances in biological regulation.

[12]  Stephen L. Abrams,et al.  GSK-3 as potential target for therapeutic intervention in cancer , 2014, Oncotarget.

[13]  C. Proud,et al.  Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles. , 2014, Advances in biological regulation.

[14]  A. Toker,et al.  Signaling specificity in the Akt pathway in biology and disease. , 2014, Advances in biological regulation.

[15]  D. Nielsen,et al.  A systematic review of dual targeting in HER2-positive breast cancer. , 2014, Cancer treatment reviews.

[16]  A. Martelli,et al.  GSK-3β , 2014, Cell cycle.

[17]  J. McCubrey,et al.  STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention , 2014, Leukemia.

[18]  J. McCubrey,et al.  Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells , 2014, Cell cycle.

[19]  N. Zengi̇n,et al.  Everolimus: a new hope for patients with breast cancer , 2014, Current medical research and opinion.

[20]  Stephen L. Abrams,et al.  Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention , 2013, Leukemia.

[21]  Y. Kanaho,et al.  Activation machinery of the small GTPase Arf6. , 2014, Advances in biological regulation.

[22]  Stephen L. Abrams,et al.  Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy. , 2014, Advances in biological regulation.

[23]  S. Schurmans,et al.  SHIP2 signaling in normal and pathological situations: Its impact on cell proliferation. , 2014, Advances in biological regulation.

[24]  B. Payrastre,et al.  Class I PI 3-kinases signaling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1. , 2014, Advances in biological regulation.

[25]  G. Mor,et al.  Targeted cancer therapy--are the days of systemic chemotherapy numbered? , 2013, Maturitas.

[26]  F. André,et al.  New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer , 2013, Current opinion in oncology.

[27]  M. Katan,et al.  PLCɛ and the RASSF family in tumour suppression and other functions. , 2013, Advances in biological regulation.

[28]  M. Falasca,et al.  Role of phospholipase C in cell invasion and metastasis. , 2013, Advances in biological regulation.

[29]  P. L. McCormack.  Pertuzumab: A Review of Its Use for First-Line Combination Treatment of HER2-Positive Metastatic Breast Cancer , 2013, Drugs.

[30]  E. Winer,et al.  Pertuzumab: Optimizing HER2 Blockade , 2013, Clinical Cancer Research.

[31]  H. Gautrey,et al.  Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression and Drug Resistance , 2013, International journal of cell biology.

[32]  R. Pazdur,et al.  First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer , 2013, Clinical Cancer Research.

[33]  Max S Wicha,et al.  HER2 and breast cancer stem cells: more than meets the eye. , 2013, Cancer research.

[34]  Y. Shyr,et al.  Phosphatase and tensin homolog deficiency and resistance to trastuzumab and chemotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Franco,et al.  An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. , 2013, The oncologist.

[36]  T. Hunt.  On the regulation of protein phosphatase 2A and its role in controlling entry into and exit from mitosis. , 2013, Advances in biological regulation.

[37]  Jayson A. Neil,et al.  Deconstructing mTOR complexes in regulation of Glioblastoma Multiforme and its stem cells. , 2013, Advances in biological regulation.

[38]  Konstantinos Thalassinos,et al.  Comparative analysis of interactions of RASSF1-10. , 2013, Advances in biological regulation.

[39]  J. Barata,et al.  IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia. , 2013, Advances in biological regulation.

[40]  I. Bièche,et al.  Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab , 2013, British Journal of Cancer.

[41]  Jenny C. Chang,et al.  Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. , 2013, Cancer research.

[42]  Javier A Menendez,et al.  Basal/HER2 breast carcinomas , 2013, Cell cycle.

[43]  R. Carlson,et al.  mTOR inhibitors in the treatment of breast cancer. , 2013, Oncology.

[44]  Michael P. Lisanti,et al.  Mitochondrial dysfunction in breast cancer cells prevents tumor growth , 2013, Cell cycle.

[45]  Dafydd G. Thomas,et al.  HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. , 2012, Cancer research.

[46]  J. McCubrey,et al.  Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. , 2013, Advances in biological regulation.

[47]  C. Erneux,et al.  SHIP2 signalling at the plasma membrane, in the nucleus and at focal contacts. , 2013, Advances in biological regulation.

[48]  H. Ichijo,et al.  Activation mechanisms of ASK1 in response to various stresses and its significance in intracellular signaling. , 2013, Advances in biological regulation.

[49]  P. Berggren,et al.  The pancreatic islet as a signaling hub. , 2013, Advances in biological regulation.

[50]  S. Schurmans,et al.  Inositol 1,4,5-trisphosphate 3-kinase B (Itpkb) controls survival, proliferation and cytokine production in mouse peripheral T cells. , 2013, Advances in biological regulation.

[51]  J. Boultwood,et al.  Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies. , 2013, Advances in biological regulation.

[52]  Jihe Zhao,et al.  The Role of chemokine receptor CXCR4 in breast cancer metastasis. , 2013, American journal of cancer research.

[53]  M. Wicha,et al.  Breast Cancer Stem Cells: We've Got Them Surrounded , 2012, Clinical Cancer Research.

[54]  J. Doroshow,et al.  The promise of antibody-drug conjugates. , 2012, The New England journal of medicine.

[55]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[56]  E. López-Bonet,et al.  Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin) , 2012, Cell cycle.

[57]  G. Mills,et al.  Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer , 2012, Breast Cancer Research.

[58]  M. Wicha,et al.  Lin28 and HER2 , 2012, Cell cycle.

[59]  Manran Liu,et al.  Antagonism of miR-21 Reverses Epithelial-Mesenchymal Transition and Cancer Stem Cell Phenotype through AKT/ERK1/2 Inactivation by Targeting PTEN , 2012, PloS one.

[60]  K. Jensen,et al.  Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma. , 2012, Cancer research.

[61]  Yuan Qi,et al.  Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers , 2012, Breast Cancer Research and Treatment.

[62]  B. Martín-Castillo,et al.  Metformin-induced preferential killing of breast cancer initiating CD44+CD24−/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts , 2012, Oncotarget.

[63]  G. Keating.  Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. , 2012, Drugs.

[64]  A. Thor,et al.  Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers , 2012, Cell cycle.

[65]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[66]  M. Wicha,et al.  Selective Targeting of Cancer Stem Cells , 2007, BioDrugs.

[67]  H. Ichijo,et al.  Activation mechanisms of ASK 1 in response to various stresses and its signi fi cance in intracellular signaling , 2012 .

[68]  Rosette Lidereau,et al.  PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups , 2012, Breast Cancer Research.

[69]  J. Trosko,et al.  Metformin Represses Self-Renewal of the Human Breast Carcinoma Stem Cells via Inhibition of Estrogen Receptor-Mediated OCT4 Expression , 2011, PloS one.

[70]  Stephen L. Abrams,et al.  Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways , 2011, Journal of cellular physiology.

[71]  Carlos L Arteaga,et al.  Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer , 2011, Breast Cancer Research.

[72]  Nikolas von Bubnoff,et al.  Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib , 2011, PloS one.

[73]  Stephen L. Abrams,et al.  Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells , 2011, Cell cycle.

[74]  Michael D. Zordan,et al.  ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer. , 2011, Genes & cancer.

[75]  A. Chariot,et al.  NF-κB, stem cells and breast cancer: the links get stronger , 2011, Breast Cancer Research.

[76]  Careen K. Tang,et al.  CXCR4 suppression attenuates EGFRvIII-mediated invasion and induces p38 MAPK-dependent protein trafficking and degradation of EGFRvIII in breast cancer cells. , 2011, Cancer letters.

[77]  Stephen L. Abrams,et al.  Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway , 2011, Leukemia.

[78]  Stephen L. Abrams,et al.  Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy , 2011, Oncotarget.

[79]  G. Mills,et al.  Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition , 2011, Oncogene.

[80]  P. Tan,et al.  Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy , 2011, Breast Cancer Research.

[81]  Jigisha P. Thakkar,et al.  A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. , 2011, The oncologist.

[82]  W. Muller,et al.  Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation , 2011, Cell cycle.

[83]  D. Riese,et al.  Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. , 2011, Experimental cell research.

[84]  G. Mills,et al.  Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. , 2010, The Journal of clinical investigation.

[85]  Adrian V. Lee,et al.  Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer , 2010, Breast Cancer Research.

[86]  S. Paik,et al.  Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  T. Speed,et al.  PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in breast cancer , 2010 .

[88]  Careen K. Tang,et al.  EGFR variant‐mediated invasion by enhanced CXCR4 expression through transcriptional and post‐translational mechanisms , 2010, International journal of cancer.

[89]  J. L. Costa,et al.  PIKing the right isoform: the emergent role of the p110β subunit in breast cancer , 2010, Virchows Archiv.

[90]  L. Wong,et al.  Mitochondrial dysfunction in human breast cancer cells and their transmitochondrial cybrids. , 2010, Biochimica et biophysica acta.

[91]  I. Ellis,et al.  PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis , 2010, Breast Cancer Research and Treatment.

[92]  Yang Zhang,et al.  EGFRvIII‐induced estrogen‐independence, tamoxifen‐resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer , 2009, International journal of cancer.

[93]  M. Wicha,et al.  Regulation of Mammary Stem/Progenitor Cells by PTEN/Akt/β-Catenin Signaling , 2009, PLoS biology.

[94]  Nicholas J. Wang,et al.  Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. , 2009, Cancer research.

[95]  G. Mills,et al.  Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. , 2009, Cancer research.

[96]  M. Wicha,et al.  HER-2, Notch, and Breast Cancer Stem Cells: Targeting an Axis of Evil , 2009, Clinical Cancer Research.

[97]  M. Rohaizak,et al.  Metaplastic Breast Carcinomas: A Report of Six Cases , 2009 .

[98]  Baljit Singh,et al.  Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways , 2008, Cancer biology & therapy.

[99]  M. Wicha,et al.  HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion , 2008, Oncogene.

[100]  Jiasen Cheng,et al.  Abrogation of G2/M arrest sensitizes curcumin‐resistant hepatoma cells to apoptosis , 2008, FEBS letters.

[101]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.

[102]  Stephen L. Abrams,et al.  Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors , 2008, Oncogene.

[103]  F. Schmitt,et al.  EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy , 2008, Expert review of molecular diagnostics.

[104]  F. Jones.  HER4 Intracellular Domain (4ICD) Activity in the Developing Mammary Gland and Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.

[105]  Sami Kilpinen,et al.  Role of ErbB4 in Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.

[106]  S. Fox,et al.  Down-Regulation of Phosphatidylinositol 3′-Kinase/AKT/Molecular Target of Rapamycin Metabolic Pathway by Primary Letrozole-Based Therapy in Human Breast Cancer , 2008, Clinical Cancer Research.

[107]  Z. Kolár̂,et al.  The status and role of ErbB receptors in human cancer. , 2008, Experimental and molecular pathology.

[108]  A. Chaudhuri,et al.  HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer , 2008 .

[109]  Stephen L. Abrams,et al.  Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. , 2008, Advances in enzyme regulation.

[110]  M. Worsham,et al.  Molecular Differentiation of Early and Late Stage Laryngeal Squamous Cell Carcinoma: An Exploratory Analysis , 2007, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[111]  G. Mills,et al.  A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. , 2007, Cancer cell.

[112]  E. Shpall,et al.  Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  M. Moasser,et al.  Targeting HER proteins in cancer therapy and the role of the non-target HER3 , 2007, British Journal of Cancer.

[114]  Mieke Schutte,et al.  Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines , 2007, Molecular Cancer Research.

[115]  L. Marrero,et al.  A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities , 2007, Oncogene.

[116]  S. Fox,et al.  EGFR mutations in exons 18-21 in sporadic breast cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[117]  Pamela N. Munster,et al.  IN HUMAN BREAST CANCER , 2007 .

[118]  M. Wicha,et al.  Selective targeting of cancer stem cells: a new concept in cancer therapeutics. , 2007, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[119]  H. Silva,et al.  Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients. , 2006, European journal of cancer.

[120]  A. Ashworth,et al.  EGFR amplification and lack of activating mutations in metaplastic breast carcinomas , 2006, The Journal of pathology.

[121]  J. Bartlett,et al.  The Role of HER1-HER4 and EGFRvIII in Hormone-Refractory Prostate Cancer , 2006, Clinical Cancer Research.

[122]  D. Riese,et al.  Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines. , 2006, Oncology research.

[123]  E. Hammond,et al.  Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. , 2005, Gynecologic oncology.

[124]  S. Lakhani,et al.  Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis , 2005, Breast Cancer Research.

[125]  W. Gerald,et al.  EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations , 2005, Modern Pathology.

[126]  Stephen L. Abrams,et al.  Conditional EGFR Promotes Cell Cycle Progression and Prevention of Apoptosis in the Absence of Autocrine Cytokines , 2005, Cell cycle.

[127]  Nachvak S.M,et al.  MITOCHONDRIAL DYSFUNCTION IN DOWN'S SYNDROME , 2005 .

[128]  J. McCubrey,et al.  Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells , 2004, Oncogene.

[129]  I. Ellis,et al.  Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma , 2004, British Journal of Cancer.

[130]  E. Hammond,et al.  Correlation between epidermal growth factor receptor family (HER1, HER2, HER3, HER4), phosphorylated akt (P-AKT) and clinical outcomes after radiation therapy in carcinoma of the cervix , 2004 .

[131]  R. Chadwick,et al.  EGFR and EGFRvIII Expression in Primary Breast Cancer and Cell Lines , 2004, Breast Cancer Research and Treatment.

[132]  Hong Zhou,et al.  Involvement of Ras Activation in Human Breast Cancer Cell Signaling, Invasion, and Anoikis , 2004, Cancer Research.

[133]  R. Nahta,et al.  HER-2-targeted therapy: lessons learned and future directions. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[134]  J. McCubrey,et al.  Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation , 2003, Leukemia.

[135]  F. Maurer,et al.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[136]  J. R. Reeves,et al.  Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.

[137]  D. Riese,et al.  A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. , 2003, Cancer letters.

[138]  G. Carpenter,et al.  ErbB-4: mechanism of action and biology. , 2003, Experimental cell research.

[139]  Careen K. Tang,et al.  Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis , 2002, International journal of cancer.

[140]  J. Nesland,et al.  EGFR family expression in breast carcinomas. c‐erbB‐2 and c‐erbB‐4 receptors have different effects on survival , 2002, The Journal of pathology.

[141]  J. McCubrey,et al.  Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[142]  J. Smyth,et al.  Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. , 2001, Cancer research.

[143]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[144]  J. Nesland,et al.  Estrogen receptor-α and C-ERBB-4 expression in breast carcinomas , 2001, Virchows Archiv.

[145]  J. Nesland,et al.  Estrogen receptor-alpha and C-ERBB-4 expression in breast carcinomas. , 2001, Virchows Archiv : an international journal of pathology.

[146]  H. Juhl,et al.  Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage. , 2001, International journal of surgical investigation.

[147]  F. Révillion,et al.  Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[148]  M. Clynes,et al.  Altered cell cycle response of drug-resistant lung carcinoma cells to doxorubicin. , 2000, European journal of cancer.

[149]  Careen K. Tang,et al.  Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. , 2000, Cancer research.

[150]  Careen K. Tang,et al.  Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. , 1999, Cancer research.

[151]  J. McCubrey,et al.  Differential-effects of viral and cellular oncogenes on the growth factor-dependency of hematopoietic-cells. , 1995, International journal of oncology.